CA2964625C - Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists - Google Patents
Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists Download PDFInfo
- Publication number
- CA2964625C CA2964625C CA2964625A CA2964625A CA2964625C CA 2964625 C CA2964625 C CA 2964625C CA 2964625 A CA2964625 A CA 2964625A CA 2964625 A CA2964625 A CA 2964625A CA 2964625 C CA2964625 C CA 2964625C
- Authority
- CA
- Canada
- Prior art keywords
- compound
- liver disease
- fatty liver
- receptor
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462064358P | 2014-10-15 | 2014-10-15 | |
| US62/064,358 | 2014-10-15 | ||
| US201462092041P | 2014-12-15 | 2014-12-15 | |
| US62/092,041 | 2014-12-15 | ||
| PCT/US2015/055487 WO2016061195A1 (en) | 2014-10-15 | 2015-10-14 | Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2964625A1 CA2964625A1 (en) | 2016-04-21 |
| CA2964625C true CA2964625C (en) | 2023-03-07 |
Family
ID=55747256
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2964625A Active CA2964625C (en) | 2014-10-15 | 2015-10-14 | Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists |
Country Status (22)
| Country | Link |
|---|---|
| US (5) | US10238659B2 (https=) |
| EP (2) | EP3206692B1 (https=) |
| JP (1) | JP6761410B2 (https=) |
| KR (1) | KR102435956B1 (https=) |
| CN (2) | CN111557942B (https=) |
| AU (1) | AU2015333645B2 (https=) |
| BR (1) | BR112017007860B1 (https=) |
| CA (1) | CA2964625C (https=) |
| DK (1) | DK3206692T3 (https=) |
| ES (1) | ES2978871T3 (https=) |
| FI (1) | FI3206692T3 (https=) |
| IL (1) | IL251729B (https=) |
| MX (1) | MX2017004943A (https=) |
| NZ (1) | NZ731060A (https=) |
| PH (1) | PH12017500710B1 (https=) |
| PL (1) | PL3206692T3 (https=) |
| PT (1) | PT3206692T (https=) |
| RU (1) | RU2718921C2 (https=) |
| SG (1) | SG11201703024VA (https=) |
| UA (1) | UA123537C2 (https=) |
| WO (1) | WO2016061195A1 (https=) |
| ZA (1) | ZA201702813B (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111557942B (zh) | 2014-10-15 | 2023-10-03 | 科赛普特治疗学股份有限公司 | 使用糖皮质激素和盐皮质激素受体拮抗剂的脂肪肝疾病治疗 |
| JP7196201B2 (ja) | 2018-06-04 | 2022-12-26 | コーセプト セラピューティクス， インコーポレイテッド | ピリミジンシクロヘキセニル糖質コルチコイドレセプター調節因子 |
| EP4653047A3 (en) | 2019-03-18 | 2026-02-18 | Nieman, Lynnette K. | Mifepristone for use in improving insulin sensitivity |
| KR102911885B1 (ko) * | 2020-05-06 | 2026-01-12 | 코어셉트 쎄라퓨틱스 인코포레이티드 | 피리미딘 사이클로헥실 글루코코르티코이드 수용체 조절제의 다형체 |
| JP7474869B2 (ja) * | 2020-05-06 | 2024-04-25 | コーセプト セラピューティクス， インコーポレイテッド | ピリミジンシクロヘキシルグルココルチコイド受容体モジュレーターの製剤 |
| KR102481705B1 (ko) * | 2020-08-04 | 2022-12-27 | 연세대학교 산학협력단 | 트리아졸 유도체를 유효성분으로 포함하는 간 섬유증의 예방 또는 치료용 조성물 |
| AU2021409656B2 (en) * | 2020-12-21 | 2025-04-10 | Corcept Therapeutics Incorporated | Method of preparing pyrimidine cyclohexyl glucocorticoid receptor modulators |
| CA3217413A1 (en) * | 2021-05-05 | 2022-11-10 | Ada Lee | Methods for reducing liver fat and for treating fatty liver disorders |
| WO2025174745A1 (en) * | 2024-02-12 | 2025-08-21 | Corcept Therapeutics Incorporated | MIRICORILANT TREATMENT FOR FATTY LIVER DISEASES and its EFFECTS on LIVER FAT CONTENT, FATTY ACIDS, ACYLGLYCEROLS, and SECONDARY BILE ACIDS |
| WO2025255357A1 (en) * | 2024-06-06 | 2025-12-11 | Corcept Therapeutics Incorporated | Methods for preparing and maintaining livers and portions thereof for liver transplantation |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2153546A (en) | 1936-07-29 | 1939-04-11 | Universal Draft Gear Attachmen | Hand brake actuating mechanism |
| US4391904A (en) | 1979-12-26 | 1983-07-05 | Syva Company | Test strip kits in immunoassays and compositions therein |
| GB0213745D0 (en) * | 2002-06-14 | 2002-07-24 | Univ Edinburgh | Enzyme |
| WO2004009017A2 (en) | 2002-07-18 | 2004-01-29 | Bristol-Myers Squibb Company | Modulators of the glucocorticoid receptor and method |
| ATE463479T1 (de) | 2005-05-18 | 2010-04-15 | Merck Sharp & Dohme | D-homoandrosta-17-yl-carbamat-derivate als selektive glucocorticoid-rezeptor-liganden |
| WO2007022518A2 (en) * | 2005-08-19 | 2007-02-22 | Amylin Pharmaceuticals, Inc. | New uses of glucoregulatory proteins |
| BRPI0616370A2 (pt) * | 2005-09-19 | 2011-06-14 | Johnson & Johnson Pharmaceutical Res & Dev L L C | modulaÇço da expressço de receptor de glucocorticàide |
| GB0601092D0 (en) * | 2006-01-19 | 2006-03-01 | Daniolabs Ltd | The Prevention Of Systemic Side-Effects Of Glucocorticoids |
| PL2032134T3 (pl) | 2006-05-09 | 2015-11-30 | Genzyme Corp | Sposoby leczenia stłuszczeniowej choroby wątroby obejmujące hamowanie syntezy glikosfingolipidów |
| US9623021B2 (en) | 2007-01-22 | 2017-04-18 | Gtx, Inc. | Nuclear receptor binding agents |
| CN101679445A (zh) | 2007-04-13 | 2010-03-24 | 先灵公司 | 嘧啶二酮衍生物及其应用 |
| US8003689B2 (en) | 2008-06-20 | 2011-08-23 | Gtx, Inc. | Metabolites of selective androgen receptor modulators and methods of use thereof |
| KR101739994B1 (ko) | 2009-04-03 | 2017-05-25 | 에프. 호프만-라 로슈 아게 | 프로판-１-술폰산 ｛３-［５-（４-클로로-페닐）-１Ｈ-피롤로［２，３-ｂ］피리딘-３-카르보닐］-２，４-디플루오로-페닐｝-아미드 조성물 및 그의 용도 |
| MY161170A (en) * | 2011-03-18 | 2017-04-14 | Corcept Therapeutics Inc | Pyrimidine cyclohexyl glucocorticoid receptor modulators |
| CN111557942B (zh) | 2014-10-15 | 2023-10-03 | 科赛普特治疗学股份有限公司 | 使用糖皮质激素和盐皮质激素受体拮抗剂的脂肪肝疾病治疗 |
-
2015
- 2015-10-14 CN CN202010597452.8A patent/CN111557942B/zh active Active
- 2015-10-14 KR KR1020177012950A patent/KR102435956B1/ko active Active
- 2015-10-14 SG SG11201703024VA patent/SG11201703024VA/en unknown
- 2015-10-14 JP JP2017520388A patent/JP6761410B2/ja active Active
- 2015-10-14 UA UAA201704069A patent/UA123537C2/uk unknown
- 2015-10-14 BR BR112017007860-0A patent/BR112017007860B1/pt active IP Right Grant
- 2015-10-14 WO PCT/US2015/055487 patent/WO2016061195A1/en not_active Ceased
- 2015-10-14 DK DK15851238.4T patent/DK3206692T3/da active
- 2015-10-14 EP EP15851238.4A patent/EP3206692B1/en active Active
- 2015-10-14 EP EP24157529.9A patent/EP4353310A3/en active Pending
- 2015-10-14 RU RU2017114596A patent/RU2718921C2/ru active
- 2015-10-14 NZ NZ731060A patent/NZ731060A/en unknown
- 2015-10-14 PL PL15851238.4T patent/PL3206692T3/pl unknown
- 2015-10-14 MX MX2017004943A patent/MX2017004943A/es active IP Right Grant
- 2015-10-14 CA CA2964625A patent/CA2964625C/en active Active
- 2015-10-14 AU AU2015333645A patent/AU2015333645B2/en active Active
- 2015-10-14 FI FIEP15851238.4T patent/FI3206692T3/fi active
- 2015-10-14 PT PT158512384T patent/PT3206692T/pt unknown
- 2015-10-14 CN CN201580068262.4A patent/CN107106562B/zh active Active
- 2015-10-14 US US14/883,369 patent/US10238659B2/en active Active
- 2015-10-14 PH PH1/2017/500710A patent/PH12017500710B1/en unknown
- 2015-10-14 ES ES15851238T patent/ES2978871T3/es active Active
-
2017
- 2017-04-13 IL IL251729A patent/IL251729B/en active IP Right Grant
- 2017-04-21 ZA ZA2017/02813A patent/ZA201702813B/en unknown
-
2019
- 2019-01-24 US US16/256,295 patent/US10881660B2/en active Active
-
2020
- 2020-12-03 US US17/111,288 patent/US11590135B2/en active Active
-
2023
- 2023-01-26 US US18/101,986 patent/US12226417B2/en active Active
-
2025
- 2025-01-09 US US19/014,779 patent/US20250221995A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12226417B2 (en) | Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists | |
| CN103596431B (zh) | 嘧啶环己基糖皮质激素受体调节剂 | |
| Mejia et al. | Evaluation and differential diagnosis of marked, persistent eosinophilia | |
| EP1838320A2 (en) | Cxcr4 antagonists for the treatment of medical disorders | |
| US12263169B2 (en) | Methods of treating neuroepithelial tumors using selective glucocorticoid receptor modulators | |
| KR20180116372A (ko) | 체크포인트 억제제를 강화시키기 위한 글루코코르티코이드 수용체 조정제의 용도 | |
| HK40102771A (en) | Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists | |
| HK1240087B (zh) | 使用糖皮質激素和鹽皮質激素受體拮抗劑的脂肪肝疾病治療 | |
| HK1240087A1 (en) | Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists | |
| JP2009073836A (ja) | 新規なチューブリン重合阻害物質：ベンゾイルフェニル尿素（ｂｐｕ）硫黄類似体の設計及び合成 | |
| BR112018067330B1 (pt) | Uso de moduladores de receptor de glicocorticoide para potencializar inibidores de sinalização |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20200529 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD Year of fee payment: 9 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240905 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240905 Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240905 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD Year of fee payment: 10 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250902 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250902 |